Y mAbs Therapeutics (YMAB) — Cash Flow Quality Index

Latest as of December 2022: -7.49x

Y mAbs Therapeutics (YMAB) has a Cash Flow Quality Index of -7.49x as of December 2022. Operating cash flow of $-8.66 Million is below net income of $1.16 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore cash efficiency ratio of Y mAbs Therapeutics to assess how effectively this company generates cash.

Cash Flow Quality Index

-7.49x
Operating CF / Net Income

Operating Cash Flow

$-8.66 Million
USD

Net Income

$1.16 Million
USD

Data as of

Dec 2022
Most recent filing

Annual Cash Flow Quality Index for Y mAbs Therapeutics (None–None)

Year-by-year earnings quality comparison for Y mAbs Therapeutics. For live market cap and the full company financial profile, see Y mAbs Therapeutics (YMAB) market capitalisation.

Year Quality Index Operating CF (USD) Net Income YoY Change
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.